<DOC>
	<DOCNO>NCT01833923</DOCNO>
	<brief_summary>Anlotibib ( ALTN ) kind innovative medicine approve State Food Drug Administration（SFDA） research Jiangsu Chia-tai Tianqing Pharmaceutical Co. , Ltd. ALTN kinase inhibitor receptor tyrosine multi-targets , especially VEGFR2 VEGFR3 . It obvious resistance new angiogenesis .</brief_summary>
	<brief_title>A Phase I Study Anlotinib Tolerance Pharmacokinetics</brief_title>
	<detailed_description>The primary objective trial explore maximum tolerate dose ( MTD ) , dose-limiting toxicity ( DLT ) ALTN rational dosage regimen phase II study , investigate pharmacokinetics single multiple dos ALTN 5mg/d,10mg/d,16mg/d,12mg .</detailed_description>
	<criteria>1. late malignant tumor patient diagnose pathological and/or cytological ; 2. lack standard treatment treatment failure ; 3 . 1865years , ECOG:01 , Expected survival period &gt; 3 month ; 4. stop medicine &gt; 30 day chemotherapy drug use . 5 . HB≥90g/L , ANC ( Absolute Neutrophil Count ) ≥1.5×109/L；PLT ≥100×109/L , BIL/ALT/AST ( aspartate aminotransferase ) /Cr normal range , CCR≥60ml/min , TG≤ 3.0mmol/L，cholesterol≤7.75mmol/L ; LVEF≥LLN . 6 . Female agree use contraceptive study 6 month ( intrauterine device ( IUD ) , pill condom ) ; The serum urine pregnancy test negative take ALTN , nonlactation period . Male agree use contraceptive study period 6 month . 7 . Volunteer , inform consent form ( ICF ) sign , compliance . 1 . Subject diagnose malignant tumor previously meanwhile ; 2 . Participated clinical trial four week ; 3 . Has influence oral drug ( unable swallow , gastrointestinal tract resection ) ; 4 . Already diagnosed brain metastasis , spinal cord compression , cancerous meningitis , screen CT MRI finding brain soft meningeal disease patient ; 5 . Hypertension 6 . Urine protein : ++ , urinary 24 hour &gt; 1.0g ; 7 . Coagulant function abnormality : subject bleeding tendency ( active peptic ulcer ) receive thrombolysis anticoagulant therapy ; 8 . Subject psychiatric drug abuse history ca n't get rid , mental disorder ; 9 . With artery/venous thrombotic oral ALTN ; 10 . With history anticoagulant , vitamin K antagonist ( warfarin heparin ) analogues treatment ; 11 . With Abnormal thyroid function ; 12 . With history psychiatric drug abuse mental disorder ; 13 . Viral hepatitis B hepatitis c patient ( include hepatitis b , hepatitis c virus carrier ) ; 14 . Have immunodeficiency history ; 15 . According researcher 's judgment , concomitant diseases seriously endanger patient obstruct patient complete clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Advanced cancer</keyword>
</DOC>